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Although most human retrotransposons are inactive, both inactive and active retrotransposons drive genome evolution
and may influence transcription through various mechanisms. In humans, three retrotransposon families are still active,
but one of these, SVA, remains mysterious. Here we report the identification of a new subfamily of SVA, which ap-
parently formed after an alternative splicing event where the first exon of theMAST2 gene spliced into an intronic SVA and
subsequently retrotransposed. Additional examples of SVA retrotransposing upstream exons due to splicing into SVA
were also identified in other primate genomes. After molecular and computational experiments, we found a number of
functional 39 splice sites within many different transcribed SVAs across the human and chimpanzee genomes. Using
a minigene splicing construct containing an SVA, we observed splicing in cell culture, along with SVA exonization events
that introduced premature termination codons (PTCs). These data imply that an SVA residing within an intron in the same
orientation as the gene may alter normal gene transcription either by gene-trapping or by introducing PTCs through
exonization, possibly creating differences within and across species.
[Supplemental material is available online at http://www.genome.org. The 59 RACE sequence data from this study have
been submitted to dbEST (http://www.ncbi.nlm.nih.gov/dbEST) under accession nos. GR564526–GR564716.]
Most eukaryotic genomes harbor retrotransposable elements
(Malik et al. 1999). About 35% of the human genome is derived
from retrotransposed sequences such as LINE-1, Alu, SVA, endog-
enous retroviruses, and processed pseudogenes (Lander et al.
2001). Although most human retroelement copies are no longer
mobile, both active and inactive human elements have been
shown to drive genome evolution and influence gene expression
(Moran et al. 1999; Han et al. 2004; for reviews, see Belancio et al.
2008; Goodier and Kazazian 2008).
SVA RNAs are hominid-specific noncoding RNAs, which vary
in size from 700–4000 bp, and are likely mobilized by the human
LINE-1 in trans (Ono et al. 1987; Shen et al. 1994; Ostertag et al.
2003; Wang et al. 2005), similar to the human Alu (Dewannieux
et al. 2003). There are roughly 2700 SVA copies in the human ge-
nome (Wang et al. 2005). A canonical full-length SVA (Fig. 1A)
contains a number of sequence features proceeding from its 59 end:
(1) a CCCTCT hexameric repeat, ranging in repeat number from
a few to as many as 71; (2) a sequence that shares homology with
two antisense Alu fragments; (3) a variable number of tandem re-
peat sequence (VNTR); and (4) a sequence derived from the ENV
gene and right LTR of an extinct HERV-K, hereafter referred to as
SINE-R. SVAs typically terminate at their own polyA signal, with
genomic insertions usually containing a number of adenines at the
39 end. A target site duplication common to other LINE-1-driven
retroelements (6–20 bp) flanks the inserted element (Ostertag et al.
2003).
Little is known about the biology of SVA apart from its
structure. SVAs are currently active in the human genome, as in-
dicated by the identification of de novo SVA insertions associated
with disease (Hassoun et al. 1994; Rohrer et al. 1999; Makino et al.
2007). SVA disease insertions are associated with exon-skipping
(Hassoun et al. 1994; Rohrer et al. 1999), deletion of genomic DNA
(Takasu et al. 2007), and reduced or absent mRNA expression
(Kobayashi et al. 1998; Wilund et al. 2002; Makino et al. 2007). In
a manner similar to L1, SVAs have been shown to transduce 39
flanking sequences to new genomic locations (Moran et al. 1999;
Ostertag et al. 2003; Xing et al. 2006). SVAs are thought to be
highly active due to the ratio of disease insertions to genomic
copies. Furthermore, the high levels of insertion polymorphism of
the human-specific subfamilies, E and F (Bennett et al. 2004;Wang
et al. 2005), support the notion that SVAs are evolutionarily young
and relatively active in the human population.
The mechanism of SVA transcription and the location of its
promoter are unknown and are critical to our understanding of
SVA retrotransposition. To date, experiments to characterize the
SVA promoter have led to ambiguous results. Recently, we reex-
amined an SVA insertion on CH6 associated with a genomic de-
letion including the entireHLA-A gene that resulted in leukemia in
three Japanese individuals (Takasu et al. 2007). The HLA-A in-
sertion led to several interesting findings, including the identifi-
cation of a new SVA subfamily formed by alternative splicing from
the first exon of the MAST2 gene on CH1 into an SVA, and the
identification of a SVA master element on CH10. We have also
identified numerous functional 39 splice sites (SSs) within SVA
while analyzing human and chimp SVA 59 transcriptional start
sites (TSSs), and three more examples where splicing into the SVA
followed by retrotransposition led to exon shuffling. Using
a minigene construct containing an intronic SVA, we are able to
show that splicing into the SVA is not rare and that this splicing
results in both exonization and SVA gene-trapping. These data
suggest that splicing into SVA elements enables their expression
and can allow for adaptive evolution at the cost of altering the
transcriptome in both humans and great apes.
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Results
Identification of MAST2-SVA
In 2007, Takasu et al. described a 14-kb deletion that included the
entireHLA-A locus in three unrelated families, leading to leukemia
in one individual fromeach of the families. Analysis of the deletion
site identified an SVA insertion, hereafter referred to as SVAHLA-A.
Using the SVAHLA-ADNA sequence, we located an SVA insertion on
chromosome 3p21.31 as the likely progenitor of the SVAHLA-A in-
sertion (Takasu et al. 2007). Further analysis of SVAHLA-A and its
progenitor revealed several interesting details.
First, when using BLAST (Altschul et al. 1990) to align the
SVAHLA-A sequence to the reference genome, many hits were
obtained, most being SVAs. However, a few hits had a unique se-
quence upstream of the SVA. The unique sequence juxtaposed to
the SVAHLA-A query sequence mapped with 99% identity (210/211
nucleotides [nt]) to the 59 UTR and the first exon of the MAST2
(M2) gene on chromosome 1. Further analysis showed that 262 nt
of the SVAHLA-A sequence mapped to MAST2; however, both the
SVAHLA-A and CH3 insertions had a 40-bp deletion of nucleotides
210–249 relative to the MAST2 59 UTR. Bioinformatics analysis
identified 73 SVAs (Supplemental Table 1) containing some frac-
tion of the MAST2 59 UTR and first exon in the human genome.
Subsequent analyses concluded that 39 SVA sequences containing
MAST2-derived 59 ends cluster together phylogenetically in
a clade, consistent with this subgroup being derived from
a founder event. Moreover, sequence analysis grouped theMAST2-
SVAs with the youngest human-specific SVA subfamily (F), a result
consistent with the absence of SVAs containing MAST2 59 trans-
ductions in the chimpanzee reference sequence. Hereafter, the
MAST2-SVA subfamily will be referred to as SVAF1.
The number of nucleotides derived
from MAST2 directly upstream of SVA
varied from 35–382 (Supplemental Table
1). Given that theMAST2 59UTR and first
exon combined is 460 nt, no SVAF1s
present in the human reference genome
contains the entire 59 UTR-first exon.
The MAST2 sequence abutting the
genomic copies of SVA in SVAF1 elements
terminated directly at the 59 SS of the
MAST2 first exon. However, there is no
SVA present in the reference MAST2 in-
tron sequence. It is likely that an SVAwith
an allele frequency <1 resided in intron 1
of MAST2 (Fig. 1B) in the individual
in which the first M2-SVA splicing and
subsequent retrotransposition event oc-
curred. We generated a consensus se-
quence from the SVAF1 in the human
genome and aligned it to the SVA present
in Repbase (Jurka 2000; Jurka et al. 2005),
henceforth called SVARep, to determine
whether the site where MAST2 and SVA
intersect would have provided a suitable
39 SS in a consensus SVAF1. The 39 SS
consensus sequence is YYYYYYYYYYN
CAG/G, where Y represents a pyrimi-
dine and N is any nucleotide (Wang and
Cooper 2007). The SVA portion of SVAF1
aligns to SVARep beginning at position
388 of SVARep which is located in the 39
region of the Alu-like fragment, 35 bp upstream of the VNTR. The
sequence upstream of position 388 in SVARep is CCTCCACCTCC
CAG (YYYYY-YYYYNCAG), a close match to the 39 SS consensus
sequence.
An SVA master element on CH10
The SVA on CH3, the progenitor to SVAHLA-A (Fig. 2A), lacks a target-
site duplication (TSD) directly flanking the SVAF1 (Fig. 2B). Given
that retrotransposons are able to transduce sequences 59 and 39
of their location in the genome (Moran et al. 1999; Xing et al.
2006; Goodier and Kazazian 2008), we searched for a TSD further
upstream and downstream from the CH3 SVAF1. We identified
a 15-nt TSD, with the 59 duplication directly in front of a truncated
AluSc (153 nt) and the 39 duplication following a polyA tail
downstream from a non-RepeatMasker annotated sequence. The
entire insertion between the AluSc and the terminal 39 polyA tail
nearest the 39 TSD consisted of (1) the AluSc, followed by (2)
a SVAF1, (3) an AluSp, and then (4) a 39 transduction of 82 nt 39 to
the AluSp. When using BLAT (Kent 2002) to identify the source
locus for the CH3 39 transduction, 13 hits in addition to the CH3
query sequence were obtained (Supplemental Table 2). The source
locus was identified on CH10 (Fig. 2C) due to the absence of
a polyA tail 39 of the transduced sequence present on CH3. In-
terestingly, the SVA onCH10was flanked by a 59AluSc (320 nt) and
a 39 AluSp (299 nt). Overall, 13 SVAF1 insertions contained the 39
transduction from chromosome 10 (Supplemental Table 2), and all
13 had the AluSp and were variably truncated with three contain-
ing the AluSc, four containing some portion of the MAST2 se-
quence and no AluSc, five truncated in the VNTR, and one trun-
cated in the SVA polyA tail. Furthermore, one of the SVAs, which
Figure 1. SVA and alternative splicing at the MAST2 locus. (A) The canonical SVA is displayed,
consisting of some number of CCCTCT hexameric repeats followed by the Alu-like region, a variable
number of tandem repeats, and then the SINE-R region, followed by a polyA signal with the entire SVA
flanked by target-site duplications (black arrowheads). Two black arrows over the Alu-like region in-
dicate sequence homology in the SVA to two ancestral Alu elements. (B) Shown is an ancestral CH1
MAST2 locus, sometime after the human–chimp split, containing a full-length SVA within intron 1 (top).
An alternative splicing event into the Alu-like region (black line) likely occurred resulting in the original
SVAF1 founder insertion (bottom) flanked by target-site duplications (black arrowheads) in the human
genome. Note the loss of the entire CCCTCT hexamer and most of the Alu-like region after the alter-
native splicing event. The SVA splice site relative to SVARep is aligned to the known splice site sequence
(middle).
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CH10 was the source locus for, had a 160-nt 39 transduction. This
element represents a transcript from the CH10 locus that bypassed
the polyA signal at which the other 12 elements terminated. The
sequence directly after the AluSp, the original source for these
transductions, contains two canonical polyA signals, AATAAA
(Colgan and Manley 1997), which are 15–20 nt upstream of the
polyA tails of the SVAs derived from the CH10 locus (Fig. 2C).
To distinguish whether the SVA on CH10 inserted alone, or
with the AluSc and/or AluSp, we searched for TSDs of each element
and examined the chimpanzee reference sequence (Chimpanzee
Sequencing and Analysis Consortium 2005). Only the AluSp,
hereafter referred to as 39 Alu, was present in the chimp reference
sequence, suggesting that it was the first insertion on CH10 (Fig.
3A) and that the SVA insertion occurred, with or without theAluSc,
hereafter referred to as 59 Alu, sometime since our last common
ancestorwith chimp. Furthermore, the 39Alu onCH10 is at least 25
million years (Myr) old because it is present in the Rhesus macaque
genome sequence (Rhesus Macaque Genome Sequencing and
Analysis Consortium 2007). The 59 Alu on Ch10 could be traced
back to a locus on CH9, due to 185 nt present directly upstream of
the 59 Alu on CH10 (Fig. 3E), which represents a 59 transduction
from theCH9AluSc source locus (Fig. 3C). OnCH10 there is a 13-nt
TSD flanking the 59 Alu containing the 59 transduction and the
SVA, suggesting that the 59Alu and SVA retrotransposed as one unit
(Fig. 3C). However, at the CH9 locus there is no SVA downstream
from the AluSc in the human reference sequence.
Identification of multiple SVA TSSs
SVA is a nonautonomous retrotransposon and was previously
thought to rely on an internal promoter to initiate its transcrip-
tion, similar to LINE-1 (Swergold 1990) and Alu (Di Segni et al.
1981; Duncan et al. 1981; Fritsch et al. 1981). Previous attempts in
our laboratory to locate the SVA promoter have led to ambiguous
results (MC Seleme and HH Kazazian,
unpubl.). We set out to identify the SVA
TSS for insight into how SVA mRNA is
transcribed.
We used 59 RACE to identify novel
SVA 59 ends from total RNA extracted
from cell lines (see Methods) and chim-
panzee testes. Currently, both the re-
quirements for SVA transcription and the
repertoire of expressed SVAs are un-
known.We identified a total of 56 unique
SVA-associated TSSs after sequencing and
analysis of human and chimp SVA 59
RACE products (Table 1). We grouped the
TSSs into three classes: (1) internal SVA
TSSs (Supplemental Table 3); (2) 59 TSSs,
defined as any position upstream of SVA
annotated sequence (Supplemental Table
4); and (3) examples in which part of the
sequence alignedwithin the SVA and part
aligned upstream with a large gap in be-
tween, representing transcripts where 59
sequences are spliced into the SVA part of
the transcript (Table 2). The 26 class I TSS
are scattered throughout the SVAbut tend
to cluster toward the 59 end of the ele-
ment (Fig. 4). The 14 class II TSSs start 76–
440 bp upstream of SVAs in the human or
chimp genome (Fig. 4; Supplemental Table 2).
Class III SVA-associated TSSs represent splicing into the SVA
We identified 17 class III TSSs, 16 of which are unique (13 human
and four chimp) where the 59 ends mapped upstream and repre-
sented splicing into SVA at 10 different 39 SS (Table 2). SVA splicing
events are listed in Table 2, with the 39 SS position and 39 SS se-
quence annotated relative to SVARep. Twelve of 17 class III TSSs
involved exons from known genes/ESTs. One gene, AFF1 on CH4
had two SVA alternative splicing events identified by 59 RACE,
suggesting the same SVA may contain multiple functional 39 SS.
Many SVA splicing events are present in human ESTs
To identify further examples of SVA splicing, we performed
a computational survey to identify splicing events. We focused on
splicing events involving the 228 SVA elements present in intronic
regions oriented in the same direction as the surrounding gene.
EST databases (Boguski et al. 1993) were mined for uniquely
aligned sequences with evidence of intronic SVA expression.
Spliced ESTswere selectedwhere one ormore blocks alignedwithin
the intronic SVA sequence, and the exon–SVA junctions were ex-
amined. The SVA sequences upstream and downstream from the
EST junctions were compared to the SS consensus sequence, and
those containing the canonical ‘‘(T/C)AG’’ trinucleotide (Wang
and Cooper 2007) at the junction preceded by a reasonable poly-
pyrimidine tract were kept. We defined an event as a unique exon
59 SS and a unique SVA 39 SS. If multiple overlapping ESTs having
the same 59 SS and SVA 39 SS existed, we called it one event. ESTs
with the same 59 SS and two different SVA 39 SS were called two
events.
In total, 16 events, involving 14 genes, at eight different SVA
39 SS were detected, supporting the notion that splicing into SVAs
Figure 2. Identification of the SVA master locus on CH10. (A) The SVA insertion on CH6. The 40-bp
deletion in theMAST2 sequence (4) allowed the identification of the (B) CH6 progenitor element to be
identified on CH3. The SVA insertion on CH3 contains both 59 and 39 tranductions. At the 59 end, the
SVA contains a truncated AluSc while at the 39 end, an AluSp along with additional sequence, indicated
by X, followed by a polyA tail, with the entire insertion flanked by target-site duplications. The 39
transduction (X, red line) on CH3 allowed the identification of (C ) the master element on CH10 along
with 12 additional elements derived from the CH10 locus. The SVA on CH10 contains starting at it’s 59
end: 185 bp transduction derived from CH9, a full-length AluSc, the MAST2-SVA, an AluSp, polyA tail,
and then a unique sequence, which was 39 transduced, and which allowed the identification of CH10 as
the source locus. A target-site duplication flanks the insertion, which inserted on CH10. Downstream
polyA signals are displayed over the X and Y transduction sequences.
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occurswith some frequency across the genome (Table 2).We found
one gene, C2CD3, which had ESTs aligning to three different 39 SS
locations at the C2CD3 locus, AG138, AG319, and AG386, further
indicating that multiple functional 39 SS exist within SVA.
Gene-trapping occurs in primates
The upstream sequence of all class II TSSs were aligned to either the
human or chimp reference sequence using BLAT (Kent 2002) to
determine whether the sequence was present elsewhere in the
genome, which would indicate potential SVA retrotransposed 59
transductions. Of the 14 class II TSSs, only the lone example from
chimp aligned elsewhere in the chimp reference sequence. The
sequence consisted of 423 bp upstream of a truncated SVA on
3q11.2 (Fig. 5A) that aligned to multiple genomic locations with
91%–95% identity, one of which was a 342-bp hit on 15q14 (Fig.
5B). Further analysis revealed that the SVAs on CH3 and CH15
were insertions derived from two different SVA alternative splicing
events, and that the transduced exons were derived from the
transmembrane phosphatase with tensin homology (TPTE) gene
onCH22 in chimp (CH21 inhumans).TPTE is a testis-specific gene
that shares significant homology with PTEN (Chen et al. 1999).
However, similar to MAST2, no SVA is present in the TPTE gene
reference sequence. These SVA insertions differ in that the 59 trans-
duction of the CH3 insertion is 531 bp and contains exons 1, 18, 19,
and20,while the 59 transductionof theCH15 insertion is 561bp and
contains five exons, an unannotated exon in intron 16 referred to as
16a, and exons 17, 18, 19, and 20 (Fig. 5B). TheCH3 insertion spliced
into AG 336 of SVA, while the CH15 in-
sertion spliced into AG 386. Both 39 SS
were identified previously in our data. Both
the CH3 and CH15 SVA insertions are
present in the human reference genome;
however, both are absent from the orang-
utan reference genome. We used the en-
semble browser to identify the presence of
the CH15 SVATPTE insertion in the gorilla
genome sequence, while the CH3 SVATPTE
insertion was not located.
After finding SVAF1 and SVATPTE, we
examined the human genome to see if we
could identify additional examples of
splicing followed by retrotransposition.
We searched the human genome refer-
ence sequence (Lander et al. 2001) for
SVAs that had a non-SVA sequence up-
stream present multiple times in the ge-
nome. This approach would identify
examples where an SVA provided a 39 SS
and this mRNA retrotransposed and
then likely jumped again. Computational
analysis identified an SVA subgroup,
SVARHOT1, where the first six exons, 532
bp, of the RHOT1 gene on chromosome
17, also known as mitochondrial Rho
GTPase 1 (MIRO-1) (Fransson et al. 2003),
were spliced into SVA at AG 336 and
subsequently retrotransposed (Supple-
mental Fig. 1). However, unlike the
MAST2 and TPTE examples, there is an
SVA residing in the sixth intron of RHOT1
in the human reference genome. There
are three SVAs in the human genome containing upstream RHOT1
processed exons, located on 13q11, 18p11.21, and 21q11.2. Two
SVARHOT1 copies were identified in the chimp genome on CH13
and CH18 and one on CH13 in the gorilla genome. Both the hu-
man and chimp SVARHOT1 insertions are missing the first 36 nt of
the RHOT1 59 UTR and share identical 13-nt TSDs. Surprisingly,
these different insertions represent duplications and not in-
dividual retrotransposition events. The human SVARHOT1 in-
sertions are within large CNVs, present in both human and chimp
several times, yet only the CH13, CH18, CH21 CNVs contain the
SVARHOT1 insertion (Supplemental Fig. 1). We concluded that the
CH13 SVARHOT1 insertion most likely represents the original
SVARHOT1 insertion based upon its presence in the gorilla genome
draft sequence; however, this is contingent upon the CNVs con-
taining the other SVARHOT1 insertions not being polymorphic in
these species. Both the SVA insertion in intron 6 of RHOT1 and all
of the SVARHOT1 insertions are absent from the orangutan genome
sequence, suggesting that the SVA at the RHOT1 locus and the
Figure 3. Genesis of the SVA master locus on CH10. The AluSc on CH9 and the AluSp on CH10,
hereafter 59 Alu and 39 Alu, respectively, are shown present in the human–chimp common ancestor. The
original target-site duplications (TSDs) for the 59 Alu and the 39 Alu are indicated by blue and red ar-
rowheads, respectively. (A) After the human–chimp split, the initial SVAF1 was formed due to an alter-
native splicing event. A SVA mRNA was transcribed from either the founder SVAF1 insertion or some
other unknown SVAF1 locus in the human genome, derived from the original SVAF1 founder insertion.
(B) The SVA mRNA is retrotransposed directly downstream from the 59 Alu on CH9 as displayed by the
SVA insertion flanked by TSDs (green arrowheads). (C ) Transcriptional initiation occurred upstream of
the 59 Alu, generating a composite mRNA containing in order (1) 185 nt of 59 transduced sequence from
CH9, (2) the 59 Alu, and (3) the SVAF1. (D) The composite mRNA from CH9 retrotransposed to CH10
directly upstream of the 39 Alu. (E ) The CH10master element present in the human genome reference is
shown. Directly downstream from the 39 Alu TSD, unique sequence blocks (blue boxes), labeled X and Y,
are present in the daughter insertions derived from this locus. The polyA signals utilized in the 39
transductions are indicated by AATAAA relative to the unique sequence blocks.
Table 1. SVA-associated transcriptional start sites
Class Human Chimp Total unique
I: Internal 16 10 26
II: Upstream 13 1 14
III: Splicing 13 4 16a
Total 56
aCH17 SVA splicing event was identified in both species.
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original SVARHOT1 event occurred some time after the orangutan
diverged from the human–gorilla last common ancestor, aging the
insertion between 8 and 15 Myr.
SVA splicing is not rare
To study the potential mutagenic potential of SVA splicing, we
cloned two SVAs from the human genome, SVAC2CD3 and
SVAMTFR1, containing multiple functional 39 SS. We cloned the
SVAs into the intron of a splicing mini-
gene construct named pPKC-EGFP (Fig.
6A), hereafter pPKC-SVA. 293T cells were
transfected with pPKC-SVA, and total
RNA was harvested after 1 d. To charac-
terize SVA splicing and identify func-
tional 39 SSs, we performed RT-PCR with
a forward primer in the first exon, PKC,
and then used three reverse primers (6A)
in independent reactions to answer three
questions: (1) are SVAs exonized (PKC For
+ 1R primers); (2) what 39 SS exist in SVA
(PKC For + 2R); and (3) can we detect SVA
gene-trapping (PKC For + 3R).
PCR products were analyzed on a 2% agarose gel (Fig. 6B);
bands were cloned and sequenced. Bands from the lane labeled 1R
for pPKC-SVAC2CD3 corresponded to the normal splicing, PKC
exon to EGFP exon, and also to SVA exonization events. Five SVA
exonization events utilizing three different 39 SS and three differ-
ent 59 SS with SVA exons ranging from159–359 nt (Fig. 6B; Table 3)
were identified. Three out of the five SVA exonizations shift the
reading frame, while all five SVA exonization events introduce pre-
mature stop codons (PTCs) located in the exonized SVA sequence.
Table 2. 39 Splice sites identified within SVA
Splice acceptor Sequence Gene/EST Species UCSC Genome Browser SVA subfamily Method
52 CTCTCTTCCCACAG n/a Hsa,
Ptr
chr17: 78004366–78005622 A 59 RACE
52 CTCTCTTTCCACAG FAM122C Hsa chrX: 133800359–133802069 D EST analysis
70 CCTCTCATGTGGAG CF145918 Hsa chr2: 27435097–27436626 F 59 RACE
70 CCTCTGATGCCAAG n/a Hsa chr3: 9956016–9957408 D 59 RACE
76 ATGCCGAACCGAAG SgK494 Hsa chr17: 23954622–23956451 D 59 RACE
138 TTCTCCTGCCTCAG AFF1 Hsa chr4: 88135456–88136923 D 59 RACE
138 TTCTCCTGCCTCAG DA477153 Hsa chr12: 64814008–64816131 F 59 RACE
138 TTCTCCTGCCTCAG SCYE1 Hsa chr4: 107461381–107462912 B EST analysis
138 TTCTCCTGCCTCAG CLIC4 Hsa chr1: 24997705–25000164 F EST analysis
138 TTCTCCTGCCTCAG C2CD3 Hsa chr11: 73517261–73518822 D EST analysis
138 TTCTCCTGCCTCAG MAPKAP1 Hsa chr9: 127260318–127261973 D EST analysis
138 TTCTCCTGCCTCAG ESCO1 Hsa chr18: 17425626–17427548 D EST analysis
138 TTCTCCTGCCTCAG CF145918 Hsa chr2: 27435097–27436626 F EST analysis
208 TTTTTTTGGTGGAG LOC650368 Ptr chr11: 3400235–3400597 B 59 RACE
269 GAGTGATCTGCCAG RAB7A Hsa chr3: 129974255–129975628 C EST analysis
269 GAGTGATCCGCCAG n/a Ptr chr16: 80967766–80968128 B 59 RACE
319 TCTCGTTCACGCAG C2CD3 Hsa chr11: 73517261–73518822 D EST analysis
336 Unknown TPTE Hsa chr21: 9928614–10012791a B Genome
336 TCAATGGTGCCCAG MTFR1 Hsa chr8: 66736844–66738336 D 59 RACE
336 TCAATGGTGCCCAG ELOVL5 Hsa chr6: 53277226–53279021 D 59 RACE
336 TCAATCTTGCCCAG BU159250 Hsa chr19: 11648074–11649703 B 59 RACE
336 TCAGTGTTGCCCAG RHO/T1 Hsa chr17: 27529349–27531779 A Genome
336 TCAATGTTGCCCAG VPS24 Hsa chr2: 86628818–86631061 A EST analysis
336 TCAATGTTGCCCAG n/a Ptr chr8: 142697098–142697454 B 59 RACE
386 Unknown MAST2 Hsa chr1: 46041872–46274383b F Genome
386 Unknown TPTE Hsa chr21: 9928614–10012791a B Genome
386 CCTCCACCTCCCAG SEP15 Hsa chr1: 87137058–87138908 D 59 RACE
386 CCTCCATCTCCCAG IARS Hsa chr9: 94028908–94030246 D 59 RACE
386 CCTCCACCTCCCAG MTFRI Hsa chr8: 66736844–66738336 D RT-PCR, ECR analysis
386 CCTCCACCTCCCAG SLC25A12 Hsa chr2: 172430609–172432417 D EST analysis
386 CCTCCACCTCCCAG C2CD3 Hsa chr11: 73517261–73518822 D EST analysis
386 CCTCCACCTCCCAG SLC38A9 Hsa chr5: 55026855–55028866 D EST analysis
389 CCACCTCCCAGCAG AFF1 Hsa chr4: 88135456–88136923 D 59 RACE
450 GCCATCCCATCTAG AK096668 Hsa chr5: 43613499–43615016 D 59 RACE
450 GCCATCCCATCTAG PPARD Hsa chr6: 35459078–35461415 F EST analysis
450 ACCACCCCATCTAG ZNF611 Hsa chr19: 57914830–57916788 A EST analysis
450 ACCATCCCATCTAG ORCIL Ptr chr1: 53274568–53274862 E RT-PCR
aLocation of TPTE gene in HG18.
bLocation of MAST2 gene in HG18.
Figure 4. SVAs contain many transcriptional start sites (TSSs). 59 RACE was performed on total RNA
extracted from 293T, HeLa, and nTera cell lines, along with chimp testes. A nested PCR was performed
followed by Sanger sequencing of Topo clones. The 59 RACE adaptor was identified, and the first nu-
cleotide after it was annotated as the TSS. Human (red triangles) and chimp TSS (blue triangles) within
SVA are aligned relative to the position in SVARep. The CCCTCT hexamer (Hex), Alu-like region, and part
of the VNTR are shown. TSSs aligning upstream of SVA are displayed relative to the first nucleotide of the
SVA insertion in the genome. Both human (red triangles) and chimp (blue triangles) TSSs identified by 59
RACE are shown.
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SVA splicing events using pPKC-SVA and verified by sequencing
are listed in Table 3. It is noteworthy that a 39 SS site was identified
in the SINE-R domain of SVA (Fig. 6B, lane 3, lower band). These
PCR results suggest that SVA splicing is not rare and that both SVA
exonization and SVA gene-trapping can occur in the same SVA.
Semi-quantitative RT-PCR followed by Southern blotting us-
ing amplicons from a PKC for and 1R PCR (Fig. 6A,C) was carried
out for pPKC-EGFP, pPKC-SVAC2CD3, and pPKC-SVAMTFR1 to esti-
mate SVA exonization. The intensities for normal splicing varied
across the samples, so the Southern blot was exposed overnight in
order to ensure no bandswere present in the vector-only lane (data
not shown). The ratio of the higher molecular weight bands in-
dicative of SVA exonization relative to PKC-EGFP splicing within
that lanewas determined using a phosphorimager (Fig. 6C, bottom
panel). The ratio of total SVAC2CD3 exonization relative to PKC-
EGFP splicing was 0.19:1, while total SVAMTFR1 exonization to
PKC-EGFP was 0.12:1.
Discussion
These data are the first to provide insight into how SVA retro-
transposons are expressed and how they might impact gene ex-
pression. Our data suggest that SVAs are expressed in a variety of
ways in humans and chimps. Recently, a study identified many
TSSs in LINE-1s and SINEs in human and mouse tissues and cell
lines. (Faulkner et al. 2009). Whether or not internal TSSs identi-
fied here represent retrotransposition-competent SVA transcripts is
unknown. Many SVAs have transduced sequence 59 of their loca-
tion in the genome to other locations (Damert et al. 2009); this is
consistent with our observation of upstream TSSs. What is unclear
is whether upstream TSSs represent solely upstream promoters
driving SVA expression or whether something inherent to SVA
directs transcriptional initiation upstream.
The SVAF1 subfamily, SVATPTE, and SVARHOT1 together indicate
that if an SVA loses the CCCTCT hexamer and most of the Alu-like
region due to alternative splicing into it,
the remaining SVA sequence is able to
retrotranspose. Furthermore, the lack of
most of the Alu-like region suggests that
themodel suggested byMills et al. (2007),
adapted from Boeke’s model (Boeke
1997), where the SVA Alu-like region hy-
bridizes to Alu RNAs at the ribosome in
order to compete for the LINE-1 ORF2
reverse transcriptase, may not be case.
However, it is possible that SVA RNAmay
be located at the ribosome where com-
petition for the LINE-1 ORF2 takes place,
but that it is not hybridizing to Alu RNA.
The lack of SVAF1s with a complete
MAST2 59 UTR and first exon suggests
that a full-lengthMAST259UTR first exon
is not required for transcription or retro-
transposition. Exactly, how the MAST2
sequence contributed to the expansion of
SVAF1s in the absence of the CCCTCT
hexamer and the Alu-like region still
needs to be determined. One possibility
is that the MAST2 sequence, in com-
bination with certain SVA sequence
variants or in a specific genomic con-
text, enhances transcription or retro-
transposition relative to a canonical SVA. It is worthwhile to note
that TPTE is a testis-specific gene (Chen et al. 1999) and that we
found the CH3 SVATPTE by 59 RACE, and the TSS was in exon 1 of
the transduced TPTE sequence.
We have identified 11 39 SS throughout SVA, in addition to
multiple 39 SS in the VNTR, including examples from all sub-
families except E, and we have shown that exonization can occur.
Whether or not older SVAs are still retrotransposing in humans is
currently unknown; however, the older SVAs are still able to be
transcribed and may influence transcription if residing within an
intron in the same orientation as the gene.
SSs within retrotransposons are not uncommon. Alus are
primate-specific retrotransposons that are known to exonized
(Sorek et al. 2002; Lev-Maor et al. 2003). In addition toAlu, internal
splicing has been observed in the human L1 (Belancio et al. 2006)
and the zebrafish LINE (Tamura et al. 2007). Although, it appears
that if an SVA undergoes a splicing event, it can still carry out
subsequent rounds of retrotransposition, as indicated by SVAF1.
SVA splicing followed by retrotranspositionmay be rare based
on only four examples identified in the human genome, three of
which are present in the chimpanzee. Additional splicing followed
by retrotransposition eventsmay have occurred, but the results are
undetectable due to truncation upon insertion or low allele fre-
quency. On the contrary, splicing into the SVA is not rare, as in-
dicated by our semi-quantitative PCR data, which suggest that SVA
exonization events may occur 12%–19% of the time relative to
normal splicing in our minigene.
Currently, the ratio of SVA gene-trapping to SVA exonization
has not been determined. Here we provide a low-end estimate for
SVA splicing by assessing SVA exonization using a splicing mini-
gene. Our SVA exonization estimate may be an underestimate
because SVAs contain more than 10 nonsense codons in each
reading frame on the sense strand and exonization of these se-
quences may induce nonsense-mediated decay if the exonized
SVA sequence is more than 50–55 nt upstream of the 39 most
Figure 5. SVA gene-trapping has occurred in other hominids. (A,B) Two different SVA splicing events
followed by retrotransposition derived from the TPTE locus on chromosome 21 flanked by a target-site
duplication. (A) CH3 SVA containing four processed TPTE exons that utilized AG 336. (B) CH15 SVA
containing five processed exons that utilized AG 386. (C ) The structure of SVA insertions on CH13,
CH18, and CH21 containing the six processed exons from the RHOT1 gene on CH17 with identical
target-site duplications.
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exon–exon junction (Nagy andMaquat 1998). Be that as it may, an
SVA splicing event, exonization or trapping (Fig. 7), will likely lead
to a dead-end to the protein-coding capacity of the mRNA because
either event has the capability to produce truncated proteins.
Most SSs identified using the splicing minigene were not iden-
tified by 59 RACE, such as the 39 SSs in the VNTR and SINE-R. This is
likely due to the nested PCR approach utilized in 59 RACE. However,
downstream SVA 39 SS may be selected for in the splicing minigene
due to the small size of the intron. Each SVA was cloned into pPKC-
EGFP with less than 100 bp of flanking DNA to ensure splicing was
inherent to the SVA and not due to intronic splicing enhancers. If
SVA is cloned in as a larger fragment, onemay see 39 SS selection shift
toward the 59 end of SVA residing in the Alu-like domain.
If SVAs impact gene expression by being alternatively spliced,
then one would expect to observe either a depletion of SVAs in
genes or on the coding strand of genes. An underrepresentation
was observed for SVAs on the coding-strand in the human genome;
1060/2772 SVAs are in RefSeq genes, with 228/1060 on the coding
strand (introns or exons) and 832/1060 on the antisense strand.
This underrepresentation of intronic SVA insertions on the coding
strand is highly significant (P < 2.2 3 1016) under a null hy-
pothesis of random orientation. Likewise, a similar significant
underrepresentation is observed in the chimp reference genome,
with 228 (partial overlap with the human 228) of 1024 intronic
SVAs oriented on the sense strand with respect to the surrounding
gene. Nevertheless, this SVA strand bias may be due to a factor
other than selection, such as SVA insertional preference.
Altogether, these data show that SVAs are alternatively spliced
in cell culture, in tissue, and in vivo. We speculate that SVAs may
influence local gene expression by providing alternative SSs and
might even account for some of the variation in gene expression
observed within and across hominids. As more primate genomes
are sequenced along with more studies on SVA, the impact of this
retrotransposon will become clear. Thus, although SVAs effect on
genome evolution may be less than that of L1 and Alu because of
their smaller numbers, SVA has had recent effects that are likely
growing with their continued expansion as indicated by the SVAF1
subfamily and the CH10 subgroup. In another 50 Myr, the SVA
effect on genome evolution may be much greater than that of L1
and Alu.
Table 3. Splices sites identified in SVA splicing mini-gene
Event 39 SS (C2CD3) 39 SS Sequence 59 SS (C2CD3) Exon size
Exon 386 (445) CCTCCACCTCCCAG VNTR (786) 339
Exon 468 (411) TTGGCCTCCCAAAG VNTR (786) 316
Exon VNTR (625) GCCATCCCATCTAG VNTR (986) 359
Exon VNTR (625) GCCATCCCATCTAG VNTR (786) 159
Exon VNTR (625) GCCATCCCATCTAG VNTR (902) 275
Trap VNTR (625) GCCATCCCATCTAG — —
Trap 1372 (1352) CTGTGTCCACTCAG — —
N/A 386 (445) CCTCCACCTCCCAG — —
N/A VNTR (625) GCCATCCCATCTAG — —
N/A VNTR (629) TCCCATCTAGGAAG — —
Figure 6. SVA gene-trapping and exonization are not rare. (A) Two SVAs were cloned into PKC-EGFP (Newman et al. 2006) to test the mutagenic
potential of SVA splicing. Primers used for RT-PCR are marked. (B) RT-PCR was performed on total RNA extracted from 293T cells transiently transfected
with pPKC-EGFP containing one of two different SVAs cloned into the intron. SVA exonization events (left panel) are annotated with the first and last
nucleotide of the SVA exon, all of which occur within the Alu-like and VNTR domains. A representative agarose gel displaying SVA alternative splicing
events is shown (right panel) (see Table 3). (*) Indicates bands verified by DNA sequencing to be SVA splicing events. (C ) Semi-quantitative PCR to
determine the frequency of SVA exonization. Ten cycles of PCR on cDNA from individual pPKC-EGFP, pPKC-SVAC2CD3, and pPKC-SVAMTFR1 transfections
were carried out using PKC For and 1R. PCR products were resolved on a 2% agarose gel, followed by overnight transfer to a membrane, and subsequent
probing using a DNA probe targeting the PKC exon (top panel). (*) Indicates bands quantified by a phosphorimager. Total SVA exonization was nor-
malized to PKC-EGFP splicing within each respective lane and graphed (bottom panel).
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Methods
Sequence analysis
BLAT (Kent 2002) and BLAST (Altshul et al. 1990) were used in
mapping sequences to the reference genomes. Censor (Kohany
et al. 2006) and RepeatMasker (Smit et al. 1996) were used to
identify relative positions in SVA and subfamily classification, re-
spectively.
Cell culture
293T and HeLa cells were grown in a humidified, 5% CO2 in-
cubator at 37°C in DMEM (GIBCO) supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, and 100 U/mL penicillin, 0.1
mg/mL streptomycin. nTera cells were grown as described above
except that themedia was supplemented with nonessential amino
acids.
59 RACE, cDNA synthesis, and PCR
RNA extraction was performed using the RNeasy kit (Qiagen)
according to the manufacturer’s instructions. DNase treatment
consisted of using twice the recommended amount of RQ1 RNase-
Free DNase (Promega) followed by ethanol precipitation of the
RNA. Chimp testis was used for RNA extraction (Department of
Veterinary Medicine and Surgery, University of Texas M.D.
Anderson Cancer Center, Houston, TX).
59 RACE was performed using the GeneRacer Kit (Invitrogen)
with 5 mg DNase-treated RNA as the starting material. First-strand
cDNA synthesis was performed using the supplied SuperScript III
RT kit with random hexamer primers or Array Script Reverse
Transcriptase (Ambion). All steps were carried out according to the
manufacturer’s instructions. A two-round PCR schemewas utilized
in order to enrich for SVA containing transcripts using GoTaq
(Promega) or Expand Long (Roche) according to the manufac-
turer’s instructions with 1 mL of cDNA containing the 59 RACE
adaptor. The first round of PCR consisted of reverse primers com-
plementary to the SINE-R region of SVARep. Primers complemen-
tary to the Alu-like region were used for the second round of
PCR. PCR cycling parameters consisted of variations on touch-
down PCR with the initial annealing
temperature at 60°C and cycled down
to 50°C over 40 cycles. PCR reactions
were analyzed on 1%–1.5% agarose gels.
Bands of varying size were cut out, gel
purified using QIAquick Gel Extraction
kit (Qiagen), Topo cloned (Invitrogen),
and sequenced.
RT-PCR
DNase-treated RNA was reverse tran-
scribed using random primers with the
SuperScript III First-Strand Synthesis
SuperMix (Invitrogen) according to the
manufacturer’s instructions. One micro-
liter of cDNAwas used in PCRwithGoTaq
(Promega) or Expand Long (Roche).
EST analysis
EST locations corresponding to human
genome assembly hg18 were obtained
from the UCSC Genome Browser and
stored in a local relational database along with SVA and RefSeq
gene locations. ESTs with blocks aligning unambiguously within
SVA locations present on the same strand as a RefSeq intron were
further analyzed using Perl scripts locate EST splice junctions
within the SVA. Junctions corresponding to splicing patterns
consistent with SVA gene-trapping were compared to the SS con-
sensus sequence to ensure presence of the relevant nucleotides.
SVA splicing minigene, transfection, and RT-PCR
pPKC-EGFP has been previously reported (Newman et al. 2006).
SVAs were amplified from human genomic DNA and subcloned
into Topo (Invitrogen). The SVA was then amplified as a XhoI
fragment and cloned into the XhoI site within the intron.
293T cells were seeded into T-75 flasks in order to be 50%–
80% confluent upon transfection. Twenty-four hours later, 8 mg
of each splicing minigene was transfected using 24 mL of
Fugene6 (Roche) according to the manufacturer’s instructions.
Total RNA was isolated 1 d after transfection as described above.
Five micrograms of DNase-treated RNA was reverse-transcribed
with Array Script (Ambion) using an olio dT primer. Touch-
down PCR from 59°C to 51°C over 40 cycles was performed with
elongation at 72°C for 2 min using GoTaq Master Mix (Promega)
with 1mL of cDNA as template and primers at a final concentration
of 0.2 mM per reaction. Amplicons were analyzed on 2% agarose
gels.
Semi-quantitative PCR
One microliter of oligo dT primed cDNA derived from total RNA
from splicingminigene transfections was amplified by 10 cycles of
PCR (20 sec at 94°C, 30 sec at 57°C, 1 min at 72°C) using GoTaq
MasterMix (Promega) with PKC forward and 1R primers in a 25 mL
reaction. The entire reaction was resolved on a 2% agarose gel.
Overnight alkaline transfer to N+ hybond membrane (Amersham)
was performed followed by overnight hybridization with a 182-bp
DNA probe labeled with [a-32P]dCTP targeting the PKC exon at
65°C. Reaction products were imaged using a Storm 840 phos-
phorimager (GE Healthcare) and quantified with ImageQuant 5.2
(GE Healthcare). The intensity of each band was determined fol-
lowed by the subtraction of background. SVA exonization band
Figure 7. SVA alternative splicing outcomes. An intronic truncated SVA is shown (middle). The SVA is
truncated because these SVAs are still likely to be spliced. If SVAs are exonized, they will likely generate
a truncated protein or subject the mRNA to nonsense-mediated decay due to the inclusion of SVA
nonsense codons (top). If SVAs mimic an endogenous gene-trap, that is provide a 39 SS followed by
termination at the SVA or downstream polyA signal, this may result in truncated proteins, but more
importantly the retrotransposition of exons.
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intensities were summed followed by normalization to PKC-EGFP
splicing.
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